Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy

NCT00322257 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00322257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Terminated
Start date
May 1, 2006
Completion date
April 2, 2008
Enrollment
596 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1